Gimeno F, van Veenen R, Berg W C, Steenhuis E J
Asthma Clinic, Beatrixoord Hospital, Haren (Gr.), The Netherlands.
Ann Allergy. 1988 Nov;61(5):341-3.
A placebo-controlled study was performed to compare the effect of the inhalation of ipratropium bromide as a powder (capsule = 40 micrograms) and by pressurized aerosol (two puffs of 20 micrograms; ie, 40 micrograms). Fifteen patients (nine males and six females) with chronic obstructive pulmonary disease were studied in a double-blind crossover comparison of the two different modes of administration. The VC, FEV1 and viscous work of breathing time-response curves were almost identical, indicating bronchodilation. We conclude that in patients with chronic obstructive pulmonary disease, the powder inhalation was not more effective than the pressurized aerosol. It could, however, be offered as an alternative to patients with poor hand-lung coordination. The patients tolerated the two modes of administration without difficulties: no local irritation or coughing was observed.
进行了一项安慰剂对照研究，以比较吸入溴化异丙托铵粉末（胶囊 = 40 微克）和通过压力气雾剂（两喷，每次 20 微克；即 40 微克）的效果。在一项针对 15 名慢性阻塞性肺疾病患者（9 名男性和 6 名女性）的双盲交叉比较中，研究了这两种不同给药方式。肺活量（VC）、第一秒用力呼气容积（FEV1）和呼吸粘性功的时间反应曲线几乎相同，表明有支气管扩张作用。我们得出结论，在慢性阻塞性肺疾病患者中，粉末吸入并不比压力气雾剂更有效。然而，对于手肺协调性差的患者，它可以作为一种替代方法。患者对这两种给药方式耐受良好：未观察到局部刺激或咳嗽。
